- IMPROVING TIME TO PATIENT ACCESS TO INNOVATIVE ...🔍
- A once|in|a|generation opportunity to optimise regulatory timelines ...🔍
- The root causes of unavailability of innovative medicines and delay ...🔍
- The root cause of unavailability and delay to innovative medicines🔍
- Regulatory Road to Innovation🔍
- ACCESS TO ONCOLOGY COMBINATION THERAPIES IN EUROPE🔍
- Improving the understanding🔍
- Unlocking the potential of precision medicine in Europe🔍
EFPIA Highlights three potential solutions to improve timelines ...
It also intends to find the common ground regarding solutions with the potential to reduce time to ... Figure 3 highlights the three access ...
A once-in-a-generation opportunity to optimise regulatory timelines ...
A once-in-a-generation opportunity to optimise regulatory timelines to improve time to patient access · The journey of new medicines from the ...
Finding workable solutions to improve patient access to medicines will require multi-.
Over the past three years, EFPIA has documented the root cause of access inequality and ... Policy solutions to improve availability of innovative medicines. It ...
https://efpia.eu/media/554543/novel-pricing-and-payment-models-new-solutions-to-improve-patient-access-. 300630.pdf. 6 https://www.efpia.eu/media/602581 ...
3 - https://efpia.eu/media/636486/improving-regulatory-timelines-to-optimise-patient-access-to-innovative-oncology-therapies-in-europe.pdf. 4 - https://www.
EFPIA Oncology Platform's (EOP) Journey to Improving ... During 2023, several European NTAs continued their efforts in developing potential solutions that.
EFPIA for many years has looked at the length of time it takes for medicines to be made available. As illustrated by the most recent data in the Patient ...
Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer. Cancer Rep (Hoboken). 2021. Jun;4(3):e1334 ...
This report represents the outcomes of the IQN Path, ECPC and EFPIA initiative to “improve cancer care through broader access to quality biomarker testing”.
EFPIA Disclosure Code: Frequently Asked Questions
Who is EFPIA? Why this Code now? Who is affected by this Code? Where will the Code be implemented? How will the Code be implemented? What will be disclosed? By ...
COMBINE - Public Health - European Commission
synergies and opportunities for improvement which alongside the issues raised could inform potential solutions. An overview of the outputs of this work can ...
EFPIA Statement on the use of AI - Cuatrecasas
EFPIA believes that AI has great potential to improve research, development and manufacturing of medicines, and that the existing regulatory frameworks for ...
POTENTIAL SOLUTIONS: HTA ADAPTATIONS FOR HIGH-COST INNOVATIONS ... solutions to improve patient access (2) Seattle Times. IQVIA | EFPIA ...
EFPIA: Trials Hampered by New Rules on In Vitro Diagnostics
Companies in the sector expect up to 42,200 patients to be affected by the delays over the next three years, EFPIA reports, highlighting the ...
3 Every Day Counts: Improving regulatory timelines to optimise patient ... To harness the potential of integrated solutions and to keep pace with the rapid.
Re-Envisioning Pharmaceutical Manufacturing: Increasing Agility for ...
Production at the point-of-care can only occur with a combination of manufacturing and regulatory innovation, to further enhance patient access to medicines, ...
Shaping the Future of HTA: EFPIA and ESMO weigh in on JCA ...
According to EFPIA, the JCA process needs more clarity on process, timelines, and methods to guide HTD in preparing for JCAs in 2025. There is a ...
A 10-year update to the principles for clinical trial data sharing by ...
The focus is on policy and process updates to the PhRMA/EFPIA 2013 data sharing commitments, aiming to enhance the sharing and accessibility of ...
and healthcare systems to find solutions to improve access to medicines and the sustainability of healthcare, at the same time securing future medical ...